AstraZeneca’s (NYSE:AZN) Fasrena evaluated in Phase III OSTRO trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) met both co-primary endpoints.
Fasenra demonstrated a statistically significant improvement in the endoscopic total nasal polyp score (NPS) and the nasal blockage score (NBS) compared to placebo, in patients with nasal polyposis who were still symptomatic despite continued treatment with standard of care (SoC).
SoC consists of intranasal corticosteroids and prior surgery and/or use of systemic corticosteroids.
CRSwNP is an inflammatory disease associated with elevated levels of eosinophils in the upper respiratory tract and characterised by benign growths called nasal polyps.
Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma.
Additionally, the Company will be transferring the listing of its American Depositary Receipts (ADRs) and its US-listed debt securities from NYSE to Nasdaq and Nasdaq Bond Exchange respectively, effective after market close on September 24.
ADRs and debt securities are expected to commence Nasdaq trading from September 25. The ADRs will continue to be listed as “AZN”.
“The change of stock exchange in the US will reduce overall listing cost for our equity and debt securities,” said Marc Dunoyer, Executive Director and CFO.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.